[go: up one dir, main page]

CL2017001610A1 - Anticuerpos humanos para hemagglutinina de influenza - Google Patents

Anticuerpos humanos para hemagglutinina de influenza

Info

Publication number
CL2017001610A1
CL2017001610A1 CL2017001610A CL2017001610A CL2017001610A1 CL 2017001610 A1 CL2017001610 A1 CL 2017001610A1 CL 2017001610 A CL2017001610 A CL 2017001610A CL 2017001610 A CL2017001610 A CL 2017001610A CL 2017001610 A1 CL2017001610 A1 CL 2017001610A1
Authority
CL
Chile
Prior art keywords
human antibodies
influenza hemagglutinin
bind
antibodies
influenza
Prior art date
Application number
CL2017001610A
Other languages
English (en)
Inventor
Lisa A Purcell
Jonathan Viau
William Olson
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2017001610A1 publication Critical patent/CL2017001610A1/es

Links

Classifications

    • C07K16/108—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>La presente invención provee anticuerpos monoclonales, o frgmentos que unen antígenos, que se unen a la proteína hemaglutinina de influenza (HA). También se protegen composiciones farmacéuticas que comprende el anticuerpo y el uso de ellas. Los anticuerpos son utilies para inhibir o neutralizar la actividad del virus influenza.</p>
CL2017001610A 2014-12-19 2017-06-19 Anticuerpos humanos para hemagglutinina de influenza CL2017001610A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462094752P 2014-12-19 2014-12-19
US201562152122P 2015-04-24 2015-04-24

Publications (1)

Publication Number Publication Date
CL2017001610A1 true CL2017001610A1 (es) 2018-03-09

Family

ID=55073153

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017001610A CL2017001610A1 (es) 2014-12-19 2017-06-19 Anticuerpos humanos para hemagglutinina de influenza
CL2019002196A CL2019002196A1 (es) 2014-12-19 2019-08-05 Anticuerpos humanos neutralizantes que se unen a hemaglutinina de influenza a. (divisional solicitud 201701610)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2019002196A CL2019002196A1 (es) 2014-12-19 2019-08-05 Anticuerpos humanos neutralizantes que se unen a hemaglutinina de influenza a. (divisional solicitud 201701610)

Country Status (19)

Country Link
US (3) US10392432B2 (es)
EP (1) EP3233908A2 (es)
JP (2) JP6711828B2 (es)
KR (1) KR102729973B1 (es)
CN (1) CN108064240B (es)
AU (1) AU2015364415B2 (es)
BR (1) BR112017012944A2 (es)
CA (1) CA2969749A1 (es)
CL (2) CL2017001610A1 (es)
CO (1) CO2017006580A2 (es)
EA (1) EA036953B1 (es)
IL (1) IL252659B (es)
MX (2) MX386403B (es)
MY (1) MY185320A (es)
PH (1) PH12017500949A1 (es)
SG (2) SG11201704212SA (es)
TW (2) TWI702229B (es)
UY (1) UY36458A (es)
WO (1) WO2016100807A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
CN109195629A (zh) 2016-02-24 2019-01-11 威特拉公司 流行性感冒抗体分子制剂
EP3515491A4 (en) 2016-09-21 2020-09-16 Aptevo Research and Development LLC CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCESSES
US11667697B2 (en) 2016-10-19 2023-06-06 Vanderbilt University Human orthopoxvirus antibodies and methods of use therefor
TW202311284A (zh) * 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
WO2019006162A1 (en) 2017-06-28 2019-01-03 Bluefin Biomedicine, Inc. ANTI-LY6H ANTIBODIES AND CONJUGATES ANTIBODY-MEDICINE
CA3072816A1 (en) * 2017-08-18 2019-02-21 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared antigens
BR112020014849A2 (pt) * 2018-01-26 2020-12-08 Regeneron Pharmaceuticals, Inc. Anticorpo recombinante isolado ou seu fragmento de ligação ao antígeno, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, e, método para prevenir, tratar ou melhorar pelo menos um sintoma de infecção por influenza
CN120290578A (zh) * 2018-01-26 2025-07-11 瑞泽恩制药公司 抗tmprss2抗体和抗原结合片段
EP3758749A4 (en) 2018-03-02 2022-07-06 The University of Chicago METHOD AND COMPOSITION FOR NEUTRALIZING INFLUENZA
KR20200060969A (ko) * 2018-11-23 2020-06-02 (주)셀트리온 인플루엔자 바이러스 질환을 치료하기 위한 투여 요법
KR20210126641A (ko) 2019-02-12 2021-10-20 리제너론 파아마슈티컬스, 인크. 보체 및 표적 항원에 결합하기 위해 이중 특이적 항체를 사용하는 조성물 및 방법
JP2022521819A (ja) * 2019-03-25 2022-04-12 ビステラ， インコーポレイテッド インフルエンザを処置および予防するための組成物および方法
EP3945800A1 (en) * 2019-04-03 2022-02-09 Regeneron Pharmaceuticals, Inc. Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
WO2020243572A2 (en) 2019-05-31 2020-12-03 Washington University Pan-neuraminidase inhibiting antibodies
WO2020251834A1 (en) * 2019-06-11 2020-12-17 The Rockefeller University Antibodies and methods for treatment of viral infections
EP4010021A4 (en) 2019-08-06 2023-08-30 Regents of the University of Minnesota COMPOSITIONS AND METHODS FOR TREATMENT OF SERPINB13 DISEASES
CN114761428A (zh) * 2019-10-28 2022-07-15 瑞泽恩制药公司 抗血凝素抗体及其使用方法
CN115348874A (zh) * 2020-01-24 2022-11-15 里珍纳龙药品有限公司 蛋白质-抗病毒化合物偶联物
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
IL294529A (en) 2020-02-10 2022-09-01 Regeneron Pharma Anti-tmprss2 antibodies and antigen-binding fragments
MX2022011892A (es) 2020-03-26 2022-10-18 Univ Vanderbilt Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del sindrome respiratorio agudo grave (sars-cov-2).
WO2021195485A1 (en) * 2020-03-27 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
CN113527483B (zh) * 2020-04-17 2023-09-22 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
BR112022021789A2 (pt) 2020-04-27 2023-03-07 Twist Bioscience Corp Bibliotecas de ácido nucléico variantes para coronavírus
EP4232159A1 (en) * 2020-10-23 2023-08-30 Icahn School of Medicine at Mount Sinai Sars-cov-2 antibodies and uses thereof
EP4247844A1 (en) * 2020-11-23 2023-09-27 VIR Biotechnology, Inc. Antibodies against influenza a viruses
KR102604669B1 (ko) * 2021-03-30 2023-11-21 충남대학교산학협력단 조류인플루엔자 바이러스의 ha 단백질에 특이적인 단클론항체, 및 이의 용도
EP4376895A2 (en) 2021-07-28 2024-06-05 Regeneron Pharmaceuticals, Inc. Protein-antiviral compound conjugates
CN118234750A (zh) * 2021-09-02 2024-06-21 纪念斯隆-凯特琳癌症中心 抗cd33抗体和其用途
WO2023122647A2 (en) * 2021-12-22 2023-06-29 The University Of Chicago Methods for detecting or treating influenza infections
WO2023137443A1 (en) 2022-01-14 2023-07-20 Regeneron Pharmaceuticals, Inc. Verrucarin a derivatives and antibody drug conjugates thereof
EP4626553A2 (en) 2022-11-30 2025-10-08 Regeneron Pharmaceuticals, Inc. Tlr7 agonists and antibody-drug-conjugates thereof
CN115993452B (zh) * 2023-03-23 2023-06-16 深圳市卫光生物制品股份有限公司 一种流感病毒疫苗血凝素含量测定方法及试剂盒
WO2025077869A1 (en) * 2023-10-13 2025-04-17 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ny-eso-1 antibodies and uses thereof
WO2025117727A1 (en) 2023-11-29 2025-06-05 Regeneron Pharmaceuticals, Inc. Analogs of quinoxaline/quinoline cytotoxins, linker- payloads, protein-drug conjugates, and uses thereof
WO2025160340A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025160324A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025166216A1 (en) * 2024-02-02 2025-08-07 The Board Of Regents Of The University Of Texas System Trop2-targeting antibodies and uses thereof
WO2025184137A1 (en) * 2024-02-27 2025-09-04 Adimab, Llc Influenza antibodies and methods of use thereof
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589174A (en) 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
AU2007254831B2 (en) 2006-06-02 2012-03-22 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
HRP20130163T1 (hr) 2006-09-07 2013-03-31 Crucell Holland B.V. Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba
CN102046654A (zh) 2007-03-13 2011-05-04 胡马斯有限公司 针对甲型流感病毒h5n1株系的抗体
US8540994B2 (en) 2007-05-11 2013-09-24 Temasek Life Sciences Laboratory Limited H5 subtype-specific binding proteins useful for H5 avian influenza diagnosis and surveillance
EP2716656B1 (en) 2007-06-15 2016-10-12 Xiamen University Monoclonal antibodies binding to avian influenza virus subtype H5 haemagglutinin and uses thereof
EP2207804B1 (en) 2007-09-13 2015-07-22 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin from influenza virus h5-subtype and uses thereof
EP2201039B1 (en) 2007-09-13 2015-07-15 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus h5-subtype or n1-subtype and uses thereof
FR2921928B1 (fr) 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
JP6149213B2 (ja) 2007-12-06 2017-06-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド インフルエンザウイルスに対する抗体およびその使用方法
CN102015765B (zh) 2008-02-05 2015-01-28 淡马锡生命科学研究院有限公司 用于h5亚型流感病毒通用检测的结合蛋白和表位阻断elisa
WO2009111865A1 (en) 2008-03-12 2009-09-17 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Health Reagents and methods for detecting influenza virus proteins
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
JP5586064B2 (ja) 2008-03-28 2014-09-10 国立大学法人北海道大学 抗ｈ５亜型ａ型インフルエンザウイルスヘマグルチニンモノクローナル抗体
US20100040635A1 (en) 2008-03-28 2010-02-18 Sea Lane Biotechnologies Neutralizing antibodies to influenza viruses
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
US9340603B2 (en) 2008-07-25 2016-05-17 Institute For Research In Biomedicine Neutralizing anti-influenza A virus antibodies and uses thereof
EP2328928A2 (en) 2008-08-25 2011-06-08 Dana-Farber Cancer Institute, Inc. Conserved influenza hemagglutinin epitope and antibodies thereto
AU2008365616A1 (en) 2008-12-24 2011-08-11 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof
EP2380976A4 (en) 2008-12-25 2012-11-07 Univ Osaka HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS
US8894997B2 (en) 2009-04-30 2014-11-25 Vanderbilt University Monoclonal antibodies to influenza H1N1 virus uses thereof
JP5813629B2 (ja) 2009-05-11 2015-11-17 クルセル ホランド ベー ヴェー インフルエンザウイルスｈ３ｎ２を中和可能なヒト抗体及び／または抗原結合フラグメントおよびその使用
WO2010132604A2 (en) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
EP2435475B1 (en) 2009-05-26 2018-10-17 Icahn School of Medicine at Mount Sinai Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
MY164121A (en) 2009-06-26 2017-11-30 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
EP2464383A4 (en) 2009-08-14 2013-02-13 Theraclone Sciences Inc COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF GRIP
EP2483307A1 (en) 2009-09-29 2012-08-08 Fraunhofer USA, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
JP5955781B2 (ja) 2010-02-08 2016-07-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 共通の軽鎖のマウス
JP5795340B2 (ja) 2010-03-08 2015-10-14 セルトリオン インクＣｅｌｌｔｒｉｏｎ，Ｉｎｃ． インフルエンザａ型ウイルスに対して中和活性を有するヒトｂ細胞由来のヒトモノクローナル抗体
HRP20170490T1 (hr) 2010-03-26 2017-06-02 Pomona Ricerca S.R.L. Imunoglobulini pune dužine igg izotipa sposobni za prepoznavanje heterosubtipnog epitopa neutralizacije na području stabljike hemaglutinina i njihova uporaba kao lijek protiv gripe
CA2839421C (en) * 2010-06-17 2019-12-03 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
AU2011289275A1 (en) 2010-08-12 2013-02-21 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
US8992929B2 (en) 2010-08-23 2015-03-31 Temasek Life Sciences Laboratory Limited Monoclonal antibody specific to major neutralizing epitope of influenza H5 hemagglutinin
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
WO2012045001A2 (en) 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
US8900585B2 (en) 2010-10-20 2014-12-02 New York Blood Center, Inc. Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
MX2013009357A (es) 2011-02-14 2014-02-17 Theraclone Sciences Inc Composiciones y metodos para la terapia y diagnostico de la influenza.
WO2013007770A1 (en) 2011-07-14 2013-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
DK3418300T3 (da) * 2011-07-18 2020-12-07 Inst Res Biomedicine Neutralisering af anti-influenza-a-virusantistoffer og anvendelser deraf
CA2892992A1 (en) 2011-12-02 2013-06-06 Aimm Therapeutics B.V. Influenza a virus specific antibodies
CA2865594C (en) 2012-03-08 2021-07-27 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
SG11201406769RA (en) 2012-05-10 2014-11-27 Massachusetts Inst Technology Agents for influenza neutralization
US20140086927A1 (en) 2012-09-25 2014-03-27 Fujita Health University Novel epitope and mechanism of antigen-antibody interaction in an influenza virus
AR093446A1 (es) 2012-11-13 2015-06-10 Genentech Inc Anticuerpos de antihemaglutinina y metodos de uso
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
CN113667012B (zh) 2013-10-02 2024-07-12 免疫医疗有限责任公司 中和抗甲型流感抗体及其用途
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
CN120290578A (zh) * 2018-01-26 2025-07-11 瑞泽恩制药公司 抗tmprss2抗体和抗原结合片段

Also Published As

Publication number Publication date
TWI701258B (zh) 2020-08-11
SG11201704212SA (en) 2017-06-29
US20200017576A1 (en) 2020-01-16
BR112017012944A2 (pt) 2018-05-15
CL2019002196A1 (es) 2019-12-13
MY185320A (en) 2021-05-04
JP6711828B2 (ja) 2020-06-17
US20160176953A1 (en) 2016-06-23
WO2016100807A3 (en) 2016-08-04
WO2016100807A2 (en) 2016-06-23
CN108064240B (zh) 2022-01-04
US10689436B2 (en) 2020-06-23
MX2017008186A (es) 2018-02-09
TWI702229B (zh) 2020-08-21
CN108064240A (zh) 2018-05-22
MX2021007679A (es) 2021-08-05
TW202026310A (zh) 2020-07-16
JP2018503361A (ja) 2018-02-08
US10392432B2 (en) 2019-08-27
PH12017500949A1 (en) 2017-10-02
KR20170098888A (ko) 2017-08-30
KR102729973B1 (ko) 2024-11-14
EA201791086A1 (ru) 2018-01-31
CA2969749A1 (en) 2016-06-23
JP2019055996A (ja) 2019-04-11
MX386403B (es) 2025-03-04
US20200377575A1 (en) 2020-12-03
AU2015364415B2 (en) 2021-09-02
IL252659A0 (en) 2017-07-31
SG10202010170SA (en) 2020-11-27
EP3233908A2 (en) 2017-10-25
UY36458A (es) 2016-07-29
TW201632548A (zh) 2016-09-16
AU2015364415A1 (en) 2017-06-15
US11453714B2 (en) 2022-09-27
IL252659B (en) 2021-06-30
CO2017006580A2 (es) 2017-09-29
EA036953B1 (ru) 2021-01-19

Similar Documents

Publication Publication Date Title
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
MX2018007288A (es) Anticuerpos neutralizantes para el virus de inmunodeficiencia humana.
MX389289B (es) Formulación farmacéutica acuosa que comprende el anticuerpo anti receptor de muerte programada l1 (pd-l1) avelumab.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
CY1124521T1 (el) Σκευασματα αντισωματος anti-cd19
CL2018002874A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016).
MX366180B (es) Nuevos agentes de union a ha.
MX2024006565A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
BR112019001233A2 (pt) formulação farmacêutica e uso da mesma
CL2017003240A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
BR112017006178A2 (pt) região fc, anticorpos, formulação farmacêutica e usos dos anticorpos
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
BR112016025819A2 (pt) vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
MX381232B (es) Formulación de anticuerpos.
MX2015016627A (es) Vacuna para la malaria.
BR112018075651A2 (pt) anticorpos anti-cd98 e conjugados anticorpo fármaco
CL2017002596A1 (es) Neutralización del virus chikungunya mediada por anticuerpos
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
CL2019003557A1 (es) Anticuerpos anti-trkb.
MX2018013222A (es) Anticuerpos de interferon beta y usos de los mismos.
MX2016000235A (es) Metodos y composiciones para vacunas del virus del dengue.
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
BR112016029935A2 (pt) ?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo?
BR112017027778A2 (pt) anticorpos para o fator xi e métodos de uso
TH173083A (th) โพลีวาเลนท์ hiv-1 อิมมูโนเจน